C WorldWide Group Holding A S Sells 2,102 Shares of Intersect ENT Inc (XENT)

C WorldWide Group Holding A S lessened its holdings in shares of Intersect ENT Inc (NASDAQ:XENT) by 1.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 167,333 shares of the medical equipment provider’s stock after selling 2,102 shares during the quarter. C WorldWide Group Holding A S owned approximately 0.55% of Intersect ENT worth $4,811,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of XENT. Principal Financial Group Inc. raised its position in shares of Intersect ENT by 10.1% in the first quarter. Principal Financial Group Inc. now owns 16,564 shares of the medical equipment provider’s stock valued at $651,000 after purchasing an additional 1,524 shares during the period. UBS Group AG raised its position in shares of Intersect ENT by 81.1% in the first quarter. UBS Group AG now owns 4,679 shares of the medical equipment provider’s stock valued at $184,000 after purchasing an additional 2,096 shares during the period. Strs Ohio raised its position in shares of Intersect ENT by 9.7% in the second quarter. Strs Ohio now owns 25,900 shares of the medical equipment provider’s stock valued at $969,000 after purchasing an additional 2,300 shares during the period. MetLife Investment Advisors LLC raised its position in shares of Intersect ENT by 22.2% in the second quarter. MetLife Investment Advisors LLC now owns 13,971 shares of the medical equipment provider’s stock valued at $523,000 after purchasing an additional 2,537 shares during the period. Finally, Waddell & Reed Financial Inc. raised its position in shares of Intersect ENT by 1.6% in the second quarter. Waddell & Reed Financial Inc. now owns 169,500 shares of the medical equipment provider’s stock valued at $6,348,000 after purchasing an additional 2,600 shares during the period. 90.03% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CEO Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $26.51, for a total transaction of $530,200.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction on Monday, October 8th. The stock was sold at an average price of $27.99, for a total transaction of $359,195.67. The disclosure for this sale can be found here. Insiders have sold 85,666 shares of company stock worth $2,435,926 in the last ninety days. 5.90% of the stock is currently owned by insiders.

A number of research firms have recently commented on XENT. BidaskClub lowered shares of Intersect ENT from a “hold” rating to a “sell” rating in a research report on Thursday, September 13th. Canaccord Genuity reissued a “buy” rating on shares of Intersect ENT in a research report on Wednesday, August 1st. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a research report on Thursday, August 2nd. Northland Securities reissued a “hold” rating and issued a $28.00 price target on shares of Intersect ENT in a research report on Monday. Finally, ValuEngine raised shares of Intersect ENT from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $39.67.

NASDAQ:XENT opened at $32.64 on Wednesday. Intersect ENT Inc has a 12 month low of $25.15 and a 12 month high of $42.95. The company has a market capitalization of $880.44 million, a PE ratio of -58.29 and a beta of 0.57.

Intersect ENT (NASDAQ:XENT) last announced its earnings results on Monday, November 5th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.02. Intersect ENT had a negative net margin of 17.22% and a negative return on equity of 15.01%. The business had revenue of $24.70 million for the quarter, compared to analyst estimates of $24.09 million. During the same quarter in the previous year, the firm posted ($0.15) earnings per share. Intersect ENT’s revenue was up 10.8% compared to the same quarter last year. On average, sell-side analysts forecast that Intersect ENT Inc will post -0.86 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “C WorldWide Group Holding A S Sells 2,102 Shares of Intersect ENT Inc (XENT)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/07/c-worldwide-group-holding-a-s-sells-2102-shares-of-intersect-ent-inc-xent.html.

Intersect ENT Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Read More: Are all No-Load Funds Equal?

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply